April 12, 2022

Clearsight Advises Triangle Insights Group in its Acquisition by TrialCard

Clearsight Advisors, Inc. (“Clearsight”) is pleased to announce another successful transaction in its Life Sciences Consulting practice. Clearsight served as the exclusive financial advisor to Triangle Insights Group, LLC (“Triangle” or the “Company”) in its acquisition by TrialCard, Inc. (“TrialCard”), a portfolio company of Odyssey Investment Partners, LLC (“Odyssey”). This transaction reaffirms Clearsight as a leading advisor to strategy consulting firms serving the life sciences sector.

Triangle combines deep knowledge of the life sciences industry with a customized approach, offering consulting services, R&D and portfolio strategy, new product planning, commercialization support and pricing and market access expertise. Since its founding in Durham, NC in 2013, Triangle has provided original solutions and personalized attention through 800+ projects for clients in the biopharmaceutical, diagnostic and medical device industries. The Company supports clients at each stage of the pharmaceutical lifecycle, with experience in every therapeutic area and more than 150 indications. The acquisition brings together Triangle’s deep commercialization and operational capabilities with TrialCard’s suite of leading patient and provider solutions to create a differentiated platform positioned to offer valuable strategic insights to life sciences clients.

Chris Apolito, Founding Partner at Triangle, praised the transaction, “We are thrilled for the future of Triangle with TrialCard. We are grateful to the Clearsight team for their dedication, attention to detail and relentless pursuit of our firm’s best interests.” “Clearsight’s knowledge and expertise in life sciences strategy consulting shined throughout this process and resulted in a valuable partnership,” added Barrett Rankin, Founding Partner at Triangle.

Clearsight Co-founder and Managing Director Greg Treger commented, “It was a pleasure to work with the fantastic team at Triangle. The life sciences industry evolves quickly, and Triangle has consistently positioned themselves to offer relevant, knowledgeable and original insights to their clients. TrialCard truly elevates its strategy consulting offerings with this partnership. With Odyssey’s support, we foresee a bright future for Triangle and TrialCard.”

The Clearsight deal team included Greg Treger, Tory Steel, Jonathan Holland and Ashton Mann.